TEKTURNA Drug Patent Profile

Which patents cover Tekturna, and when can generic versions of Tekturna launch?

Tekturna is a drug marketed by Noden Pharma and Lxo Ireland and is included in three NDAs. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has forty patent family members in twenty-two countries.

The generic ingredient in TEKTURNA is aliskiren hemifumarate; hydrochlorothiazide. There are four drug master file entries for this compound. Additional details are available on the aliskiren hemifumarate; hydrochlorothiazide profile page.

DrugPatentWatch^® Generic Entry Outlook for Tekturna

Tekturna was eligible for patent challenges on March 5, 2011.

There has been one patent litigation case involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for TEKTURNA

International Patents:	40
US Patents:	1
Applicants:	2
NDAs:	3
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	121
Clinical Trials:	18
Patent Applications:	156
Drug Prices:	Drug price information for TEKTURNA
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for TEKTURNA
What excipients (inactive ingredients) are in TEKTURNA?	TEKTURNA excipients list
DailyMed Link:	TEKTURNA at DailyMed

See drug prices for TEKTURNA

Recent Clinical Trials for TEKTURNA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Wayne State University	Phase 4
University of Alabama at Birmingham	Phase 4
Mayo Clinic	N/A

See all TEKTURNA clinical trials

Pharmacology for TEKTURNA

Drug Class	Renin Inhibitor
Mechanism of Action	Renin Inhibitors

Paragraph IV (Patent) Challenges for TEKTURNA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
TEKTURNA	Tablets	aliskiren hemifumarate	150 mg and 300 mg	021985	1	2014-01-27

US Patents and Regulatory Information for TEKTURNA

TEKTURNA is protected by one US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Noden Pharma	TEKTURNA	aliskiren hemifumarate	CAPSULE, PELLET;ORAL	210709-001	Nov 14, 2017		DISCN	Yes	No
Noden Pharma	TEKTURNA HCT	aliskiren hemifumarate; hydrochlorothiazide	TABLET;ORAL	022107-004	Jan 18, 2008		DISCN	Yes	No			Y
Noden Pharma	TEKTURNA HCT	aliskiren hemifumarate; hydrochlorothiazide	TABLET;ORAL	022107-001	Jan 18, 2008		DISCN	Yes	No			Y
Lxo Ireland	TEKTURNA	aliskiren hemifumarate	TABLET;ORAL	021985-001	Mar 5, 2007	AB	RX	Yes	No					Y
Lxo Ireland	TEKTURNA	aliskiren hemifumarate	TABLET;ORAL	021985-002	Mar 5, 2007	AB	RX	Yes	Yes					Y
Noden Pharma	TEKTURNA HCT	aliskiren hemifumarate; hydrochlorothiazide	TABLET;ORAL	022107-003	Jan 18, 2008		DISCN	Yes	No			Y

International Patents for TEKTURNA

See the table below for patents covering TEKTURNA around the world.

Country	Patent Number	Title	Estimated Expiration
Austria	183997
Australia	1642095
Australia	1642195
Australia	1642395
Australia	699616
Brazil	1100656

Supplementary Protection Certificates for TEKTURNA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1602370	CA 2009 00010	Denmark		PRODUCT NAME: ALISKIREN, SOM DETS FRIE BASE ELLER DETS FARMACEUTISK ACCEPTABLE SALTFORM, SAMT HYDROCHLORTHIAZID ELLER DETS FARMACEUTISK ACCEPTABLE SALTFORM, HERUNDER ALISKIREN HEMIFUMARAT OG HYDROCHLORTHIAZID; NAT. REG. NO/DATE: EU/1/08/491/001-080 20090116; FIRST REG. NO/DATE: CH 58935 01-04 20081028
1602370	C300385	Netherlands		PRODUCT NAME: ALISKIREN, DESGEWENST IN DE VORM; REGISTRATION NO/DATE: 58935 01-04 20081028
1602370	09C0020	France		PRODUCT NAME: COMBINAISON COMRENANT L’ALISKIREN SOUS FORME DE BAE LIBRE OU UN SEL DE CELUI-CI PHARMACEUTIQUEMENT ACCEPTABLE, ET L’HYDROCHLOROTHIAZIDE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; REGISTRATION NO/DATE IN FRANCE: EU/1/08/491/001 DU 20090116; REGISTRATION NO/DATE AT EEC: 58935 01-04 DU 20081028
1602370	SPC/GB09/024	United Kingdom		PRODUCT NAME: COMBINATION COMPRISING ALISKIREN, AS THE FREE BASE OR AS A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND HYDROCHLOROTHIAZIDE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTERED: CH 5893501 20081028; CH 5893502 20081028; CH 5893503 20081028; CH 5893504 20081028; UK EU/1/08/491/006 20090116; UK EU/1/08/491/002 20090116; UK EU/1/08/491/003 20090116; UK EU/1/08/491/004 20090116; UK EU/1/08/491/005 20090116; UK EU/1/08/491/007 20090116; UK EU/1/08/491/080 20090116; UK EU/1/08/491/074 20090116; UK EU/1/08/491/075 20090116; UK EU/1/08/491/076 20090116; UK EU/1/08/491/077 20090116; UK EU/1/08/491/078 20090116; UK EU/1/08/491/079 20090116; UK EU/1/08/491/068 20090116; UK EU/1/08/4
1602370	2009/010	Ireland		PRODUCT NAME: ALISKIREN OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND HYDROCHLOROTHIAZIDE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF.; NAT REGISTRATION NO/DATE: EU/1/08/491/001-EU/1/08/491/080 20090116; FIRST REGISTRATION NO/DATE: 58935 01 58935 02 58935 03 58935 04 20081028
1915993	C300625	Netherlands		PRODUCT NAME: COMBINATIE BEVATTENDE ALISKIREN, OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN, EN AMLODIPINE, OF EEN FARMACEUATISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/11/686/001-056 20110414

Last updated: June 25, 2026

Market dynamics and financial trajectory for TEKTURNA (aliskiren)

Executive summary: TEKTURNA (aliskiren) has transitioned from blockbuster positioning to sustained low-volume revenue as safety-driven label restrictions and a largely stalled modern prescribing mix reduced uptake in hypertension and diverted long-term growth expectations. Financial trajectory has been dominated by (1) post-marketing safety scrutiny (notably renin-angiotensin system dual blockade safety), (2) loss of major guideline share versus ACE inhibitor/ARB backbones, and (3) competitive pressure from entrenched generics and fixed-dose combinations. Launch economics in the US and ex-US are structurally constrained by the small remaining differentiated use set and by rapid price erosion once generic entry became feasible.

---

Why did TEKTURNA lose market share despite being a first-in-class renin inhibitor?

Short answer: TEKTURNA’s differentiation eroded as safety signals limited broad use and clinicians reverted to ACE inhibitors and ARBs, which kept guideline positions and benefited from lower-cost combination strategies.

What clinical and label factors constrained use?

TEKTURNA is a direct renin inhibitor. After pivotal outcomes, regulators and payers narrowed the eligible population, particularly where risk of renal impairment, hyperkalemia, and hypotension increases with dual blockade.

Key commercialization impact points:

• Restricted co-administration: The strongest commercial headwinds came from limits on combining aliskiren with ACE inhibitors or ARBs, which reduced the addressable market for “RAAS optimization” strategies.
• Outcome and risk perception: The market narrative shifted from “new mechanism” to “restricted safety profile,” impacting prescriber comfort.
• Guideline alignment: Once ARBs and ACE inhibitors remained the standard-of-care, TEKTURNA’s incremental value declined, reducing new starts.

How did safety constraints translate into prescribing behavior?

Safety-linked label restrictions typically affect three revenue levers:

1. New patient starts fall when clinicians prefer options with fewer interaction constraints.
2. Switching slows because TEKTURNA becomes a second-line or niche choice.
3. Payer restriction increases via prior authorization and step therapy, particularly as generics of ARBs/ACE inhibitors expanded.

---

What is the competitive landscape for direct renin inhibition in hypertension?

Short answer: TEKTURNA competes within a crowded hypertension market where ARBs/ACE inhibitors, thiazide diuretics, calcium channel blockers, and fixed-dose combinations already cover most guideline pathways, leaving TEKTURNA with limited differentiation.

Which drug classes displaced TEKTURNA most?

• ACE inhibitors and ARBs: Persistent first-line selection and deep generic penetration in most geographies.
• Calcium channel blockers and thiazides: Strong cost-effectiveness, broad dosing simplicity.
• Fixed-dose combination therapy: ARB/CCB and ACE/diuretic combos reduced the need for alternative mechanism agents.

How do price and formulary pressure affect TEKTURNA revenue?

• Generic substitution risk: Once the market has generic options in the same class, wholesalers and PBMs drive utilization toward lower net price products.
• Net price compression: Even where TEKTURNA remained available, payer-driven discounts and contracting pressure suppress premium pricing.

---

When does TEKTURNA face generic entry pressure and how does it affect sales?

Short answer: TEKTURNA’s financial trajectory is structurally linked to the timing of patent expiry and the scale of generic availability in core markets, which triggers rapid net sales contraction due to price erosion and switching.

What generic entry risks exist for aliskiren?

• Molecule-level availability: After patent/exclusivity windows closed, aliskiren’s base compound became a generic candidate in multiple jurisdictions.
• Formulation and strength coverage: Generics can enter across strengths and common dosage forms, limiting opportunities to defend share via minor differentiation.
• Switching dynamics: Hypertension is chronic therapy where switching is common when drug costs change, especially after payer formulary updates.

How do generic launches typically change revenue curves?

• Short-term spike in substitution as prescriptions transfer.
• Sustained decline as TEKTURNA loses shelf prominence and prescriber preference.
• Residual sales become dependent on out-of-formulary patterns, patient-specific tolerability, and localized contracting.

---

What financial trajectory does TEKTURNA show across phases: launch, peak, and decline?

Short answer: TEKTURNA followed a common trajectory for novel mechanism hypertension drugs: early growth then flattening once safety perceptions hardened, followed by structural erosion as competitive coverage and generic economics took over.

Launch and uptake phase

Early revenue depends on:

• Mechanism novelty marketing
• Payer and prescriber adoption
• Incremental guideline inclusion

For TEKTURNA, adoption did not translate into durable leadership because safety restrictions narrowed long-term growth.

Peak phase drivers and what eventually weakened

• Market access: Success required broad formulary inclusion.
• Clinical positioning: Broad RAAS substitution appeal weakened.
• Competitive counter-moves: Generics and combination strategies improved ROI for alternatives.

Decline phase drivers

• Safety label tightening reduced expansion.
• Erosion from established standards reduced new patient starts.
• Generic availability reduced net price and share.

---

What is the US regulatory and exclusivity status of TEKTURNA and how does that shape market access?

Short answer: TEKTURNA’s long-term market access is determined by the interaction of drug approvals, patent expirations, and generic competition. The commercialization outcome has been consistent with post-exclusivity market share loss.

What FDA-related dynamics typically matter for TEKTURNA sales?

• Label restrictions: They directly constrain indications and comorbidity pathways.
• Competition timeline: When exclusivity ends and generics enter, payers push substitution.
• Real-world persistence: Hypertension persistence varies and is sensitive to copay and net price.

---

What patents and Orange Book listings drive generic timing risk for aliskiren?

Short answer: Generic launch risk for aliskiren is driven by expiration of drug substance and formulation patents plus any method-of-use coverage. Without a live Orange Book dataset in this response, the specific Orange Book listing set cannot be enumerated reliably here.

What patent categories usually matter for TEKTURNA commercialization

• Drug substance (aliskiren) patents
• Compositions and formulations
• Manufacturing and process patents
• Method-of-use patents tied to specific patient groups or dosing paradigms

How do formulation and method patents affect launch timing?

Even where the core molecule expires, later-expiring formulation or method claims can delay some generic strengths or indications, but payer-driven substitution still tends to accelerate after molecule-level freedom.

---

What patent litigation and settlement dynamics affect TEKTURNA generic entry?

Short answer: Patent litigation is a major timing variable for generic entry, but the specific case docket, filing dates, and settlement terms are not provided in the input. Without those specifics, litigation-driven timing cannot be accurately mapped in this response.

Common litigation patterns in branded hypertension products

• Paragraph IV filings after perceived patent weaknesses
• Injunction settlements to delay generic launch to a defined “trigger” date
• Design-around via formulation/process changes

---

How does TEKTURNA revenue compare with major branded alternatives in hypertension?

Short answer: TEKTURNA’s revenue profile historically underperformed the dominant branded and later generic-dominated segments because safety-constrained positioning limited patient share and because chronic hypertension formularies moved to lower-cost or better-accepted alternatives.

Competitive comparison dimensions that matter

• Guideline status and default use
• Net price and payer tier placement
• Combination availability and dosing convenience
• Generic share and substitution intensity

---

Which commercial levers still worked for TEKTURNA after safety constraints?

Short answer: Market survival depended on narrow levers: residual patient segments, contracting in specific formularies, and clinical familiarity in constrained use cases.

Residual demand sources

• Patients stabilized on TEKTURNA with tolerability benefits relative to alternatives.
• Regions or payers with less aggressive substitution or different contracting.

What levers mattered less over time

• Mechanism differentiation: reduced incremental value once RAAS-standard options dominated and safety concerns widened.
• Premium pricing: became difficult under generic pressure.

---

How could biosimilar risk apply to TEKTURNA?

Short answer: TEKTURNA is a small-molecule drug; biosimilar frameworks do not apply. The market risk is generic competition and label-restricted utilization, not biologic pathway substitutes.

---

What commercial risks remain for investors or business partners tied to TEKTURNA?

Short answer: The primary risks are reduced addressable market due to label restrictions and ongoing net price compression from generic competition in hypertension.

Risk map

• Utilization risk: constrained by safety label and guideline alignment.
• Price risk: compressed by generic substitution and payer contracting.
• Channel risk: reduced pull-through once wholesalers and PBMs deprioritize non-preferred products.
• Regulatory risk: safety updates can further narrow utilization.

---

Key Takeaways

• TEKTURNA’s market dynamics shifted from mechanism novelty to safety-constrained niche utilization.
• Competitive displacement by ACE/ARB-based regimens and fixed-dose combinations reduced new starts.
• Generic entry economics drive long-term revenue erosion in chronic hypertension markets, with substitution accelerating after exclusivity windows end.
• The financial trajectory is best explained by label restriction plus payer-driven market access loss, followed by structural price compression under generic competition.

---

FAQs

1) Why do direct renin inhibitors like aliskiren have lower long-term uptake in hypertension?
Safety label constraints, limited guideline preference versus ACE inhibitors/ARBs, and payer step-therapy reduce new starts and persistence.

2) What drives TEKTURNA sales decline after exclusivity ends?
Generic substitution in chronic therapy plus steep net price compression typically cause rapid share loss.

3) How do RAAS combination restrictions change the addressable market for aliskiren?
They remove a large segment of “dual blockade” use-cases, narrowing the pool of eligible patients and reducing incremental prescribing.

4) Does TEKTURNA face biosimilar competition?
No. TEKTURNA is a small-molecule product; competition is generic substitution, not biosimilars.

5) What formulation or method-of-use claims can still matter after drug substance expiration?
Later-expiring formulation or method-of-use patents can delay certain generic strengths or label-specific claims, but payer substitution still drives overall decline once core exclusivity lapses.

---

References (APA)

1. U.S. Food and Drug Administration. (n.d.). Drug labels and prescribing information for aliskiren (TEKTURNA). FDA.
2. U.S. Food and Drug Administration. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations (aliskiren). FDA.
3. Manufacturer prescribing information history for TEKTURNA (aliskiren). (n.d.). FDA label repository.

DrugChatter Q&A for TEKTURNA

Is tekturna still on the market?